These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37821217)

  • 1. Response to - Letter to the editor 'Transparietal diffusion of polidocanol: Potential complication of sclerotherapy?'.
    Kang M; Parsi K
    Phlebology; 2023 Dec; 38(10):700. PubMed ID: 37821217
    [No Abstract]   [Full Text] [Related]  

  • 2. Transparietal diffusion of polidocanol: Potential complication of sclerotherapy?
    Ramelet AA; Bossart S
    Phlebology; 2023 Dec; 38(10):698-699. PubMed ID: 37644640
    [No Abstract]   [Full Text] [Related]  

  • 3. Ischaemic neurological deficit after sclerotherapy.
    Trenkwalder P; Lydtin H
    Lancet; 1994 Mar; 343(8900):794. PubMed ID: 7907752
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of sclerotherapy with polidocanol in children with internal hemorrhoids.
    Watanabe T; Ohno M; Tahara K; Tomonaga K; Ogawa K; Takezoe T; Fuchimoto Y; Fujino A; Kanamori Y
    Pediatr Int; 2021 Jul; 63(7):813-817. PubMed ID: 33045763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation.
    Marrocco-Trischitta MM; Guerrini P; Abeni D; Stillo F
    Dermatol Surg; 2002 Feb; 28(2):153-5. PubMed ID: 11860427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of polidocanol sclerotherapy in alleviating symptoms in patients with venous malformations.
    Guzelbey T; Cingoz M; Erdim C; Mutlu IN; Kılıckesmez O
    J Vasc Surg Venous Lymphat Disord; 2024 Mar; 12(2):101698. PubMed ID: 37890587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible ischaemic neurological deficit after sclerotherapy of varicose veins.
    Van der Plas JP; Lambers JC; Van Wersch JW; Koehler PJ
    Lancet; 1994 Feb; 343(8894):428. PubMed ID: 7905592
    [No Abstract]   [Full Text] [Related]  

  • 8. Subclinical, primary antiphospholipid syndrome unmasked by sclerotherapy.
    James MP; Grech H
    Br J Dermatol; 2002 Mar; 146(3):527-8. PubMed ID: 11952562
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.
    Bossart S; Daneluzzi C; Cazzaniga S; Ramelet AA; Uthoff H; Seyed Jafari SM; Baumgartner M; Hunger RE; Heidemeyer K; Willenberg T
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):274-283. PubMed ID: 36196455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reversible cardiac arrest after polidocanol endoscopic sclerotherapy of esophageal varices in infants].
    Bernard PH; Lamouliatte H; Boulard A; Galperine I; Quinton A
    Gastroenterol Clin Biol; 1991; 15(5):456-7. PubMed ID: 2070970
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sclerotherapy of idiopatic hydrocele with polidocanol: a study about 190 cases].
    Sallami S; Binous MY; Ben Rhouma S; Chelif M; Hmidi M; Nouira Y; Ben Rais N; Horchani A
    Tunis Med; 2011 May; 89(5):440-4. PubMed ID: 21557180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The French polidocanol study on long-term side effects: a survey covering 3,357 patient years.
    Guex JJ; Schliephake DE; Otto J; Mako S; Allaert FA
    Dermatol Surg; 2010 Jun; 36 Suppl 2():993-1003. PubMed ID: 20590706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regarding extensive tissue necrosis following high concentration sclerotherapy for varicose veins.
    Fisher DA
    Dermatol Surg; 2000 Nov; 26(11):1082. PubMed ID: 11096404
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of male varicoceles by transcatheter polidocanol foam sclerotherapy: evaluation of clinical success, complications, and patients' satisfaction with regard to alternative techniques.
    Ali A; Wirth S; Treitl KM; Treitl M
    Eur Radiol; 2015 Oct; 25(10):2889-97. PubMed ID: 25796582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and spider vein sclerotherapy.
    Schuller-Petrović S; Pavlović MD; Neuhold N; Brunner F; Wölkart G
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):983-6. PubMed ID: 21740464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerotherapy update: polidocanol is approved in the United States.
    Bergstrom KG
    J Drugs Dermatol; 2010 Jul; 9(7):871-3. PubMed ID: 20677547
    [No Abstract]   [Full Text] [Related]  

  • 17. Polidocanol for endovenous microfoam sclerosant therapy.
    Eckmann DM
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1919-27. PubMed ID: 19912070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerotherapy of hydroceles with polidocanol.
    Fuse H; Sakamoto M; Fujishiro Y; Katayama T
    Int Urol Nephrol; 1994; 26(2):199-204. PubMed ID: 8034431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unusual complication of facial sclerotherapy.
    Hoffman K
    Dermatol Surg; 2003 Apr; 29(4):423-4. PubMed ID: 12656827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol.
    Künzlberger B; Pieck C; Altmeyer P; Stücker M
    Dermatol Surg; 2006 Nov; 32(11):1410-3. PubMed ID: 17083597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.